Pfizer’s COVID jab shows promising results in SA
According to a media release by Discovery Health CEO Ryan Noach, an analysis of over 46 000 people who received the first dose of the Pfizer jab in Gauteng, 47% less of people who have been vaccinated were likely to be infected with COVID-19. People infected during the second wave were at 65% lower risk of re-infection.
Pfizer’s safety and efficacy trial showed that the jab was 95% efficacious in preventing COVID-19 of any severity in study participants who had not been infected with SARS-CoV-2 prior to vaccination. The vaccine was 100% efficacious in preventing participants from developing severe disease, as defined by the US government’s Center for Disease Control.
“Discovery Health also noted that only 8 080 (5.7%) out of a total of 141 646 vaccinated members of the medical scheme administered by Discovery Health, have submitted claims between 15 May 2021 and 29 June 2021 related to possible vaccination side-effects after their first dose.
“At this stage, our data shows, there does not seem to be a higher admission rate during this (third) wave. Gauteng health statistics show that hospital occupancy rates in both the public and private sectors are at over 90%.
“The evidence is conclusive that non-pharmaceutical - such as remaining home as far as is feasible and, when out and about ensuring mask wearing, hand hygiene,
social distancing and opting for outdoor or well-ventilated areas - work to slow down the spread of the virus.